Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by BidaskClub

researchsnappy by researchsnappy
January 27, 2020
in Healthcare Research
0
Strs Ohio Has $625,000 Stake in Collegium Pharmaceutical Inc (NASDAQ:COLL)
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Collegium Pharmaceutical Inc logoBidaskClub cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a research note released on Wednesday, January 8th, BidAskClub reports.

Several other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Collegium Pharmaceutical from a hold rating to a sell rating in a report on Tuesday, January 7th. ValuEngine cut shares of Collegium Pharmaceutical from a buy rating to a hold rating in a report on Tuesday, January 7th. Needham & Company LLC reissued a buy rating and set a $28.00 target price on shares of Collegium Pharmaceutical in a report on Monday, January 6th. William Blair reissued a buy rating on shares of Collegium Pharmaceutical in a report on Tuesday, September 17th. Finally, SunTrust Banks raised their target price on shares of Collegium Pharmaceutical to $22.00 and gave the stock a buy rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Collegium Pharmaceutical presently has an average rating of Buy and a consensus target price of $28.71.

NASDAQ COLL opened at $20.95 on Wednesday. The company has a fifty day simple moving average of $21.35 and a two-hundred day simple moving average of $15.14. The stock has a market cap of $702.45 million, a P/E ratio of -61.62, a P/E/G ratio of 3.07 and a beta of 0.80. Collegium Pharmaceutical has a 12-month low of $10.01 and a 12-month high of $24.72. The company has a current ratio of 1.24, a quick ratio of 1.20 and a debt-to-equity ratio of 0.22.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.03). The company had revenue of $72.94 million during the quarter, compared to analysts’ expectations of $74.32 million. Collegium Pharmaceutical had a negative return on equity of 13.14% and a negative net margin of 3.86%. The company’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.50) EPS. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post -0.64 earnings per share for the current year.

In other news, CEO Joseph Ciaffoni sold 64,821 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $18.77, for a total value of $1,216,690.17. Following the sale, the chief executive officer now owns 242,276 shares in the company, valued at $4,547,520.52. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 1,321 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $23.87, for a total transaction of $31,532.27. Following the completion of the sale, the executive vice president now owns 35,716 shares in the company, valued at approximately $852,540.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 386,429 shares of company stock worth $8,207,116. 8.08% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in COLL. Renaissance Technologies LLC acquired a new stake in shares of Collegium Pharmaceutical in the second quarter valued at about $3,210,000. Nuveen Asset Management LLC acquired a new position in Collegium Pharmaceutical during the second quarter worth about $2,622,000. BlackRock Inc. boosted its position in Collegium Pharmaceutical by 7.1% during the second quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock worth $32,724,000 after acquiring an additional 165,018 shares during the last quarter. Eversept Partners LP acquired a new position in Collegium Pharmaceutical during the second quarter worth about $1,854,000. Finally, Bank of Montreal Can acquired a new position in Collegium Pharmaceutical during the second quarter worth about $1,573,000. Institutional investors and hedge funds own 89.58% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: Sell-Side Analysts

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)



Receive News & Ratings for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Why credit card rewards are targeting ‘convenience’ spending | News, Sports, Jobs

Next Post

CIP funding could help grow jobs by bringing in new industry | News

Next Post
CIP funding could help grow jobs by bringing in new industry | News

CIP funding could help grow jobs by bringing in new industry | News

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com